Trial Shows FFR Technology Reduces Risk of Heart Attack

St. Jude Medical, Inc. announced that the two-year results from the landmark FAME (Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation) trial demonstrated the durability of the improved outcomes noted at one-year for patients with multivessel coronary artery disease whose treatment was guided by FFR rather than by standard angiography alone.
Earth Times